Alternative Data for Greenwich Lifesciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 116 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 12,375 | Sign up | Sign up | Sign up |
| X Mentions | 18 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Greenwich Lifesciences
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for breast and other HER2 / neu-expressing cancers. The company is headquartered in Stafford, Texas.
| Price | $26.54 |
| Target Price | Sign up |
| Volume | 174,497 |
| Market Cap | $373M |
| Year Range | $7.85 - $33.57 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
Greenwich LifeSciences Says Two Abstracts Accepted For AACR Annual Meeting 2026 As Phase III FLAMINGO-01 Trial Evaluates Fast Track GLSI-100 To Prevent Breast Cancer RecurrenceFebruary 23 - Benzinga |
|
Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01March 3 - GlobeNewswire |
|
Greenwich LifeSciences Says FLAMINGO 01 Patient Screen Rate Rose About 33% To Over 800 Per Year, With More Than 1,000 Screened And Non HLA A 02 Arm Fully Enrolled At 250 PatientsMarch 2 - Benzinga |
|
Greenwich LifeSciences shares are trading higher after the company announced that two abstracts have been accepted for presentation at the upcoming AACR Annual Meeting 2026.February 23 - Benzinga |
|
 |
Greenwich LifeSciences provides financial update on FLAMINGO-01 Phase 3 trialJanuary 27 - Thefly.com |
Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing StrategyJanuary 27 - GlobeNewswire |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 0 | 0 | -4.2M | -4.2M | -0.300 |
| Q2 '25 | 0 | 880 | -880 | -4M | -4M | -0.300 |
| Q1 '25 | 3,600 | 900 | -900 | -3.3M | -3.3M | -0.250 |
| Q4 '24 | 0 | 0 | 0 | -8M | 0 | -0.610 |
| Q3 '24 | 0 | 900 | -900 | -2.7M | -2.7M | -0.200 |
Insider Transactions View All
| Patel Snehal filed to buy 5,604,102 shares at $29.8. January 15 '26 |
| Patel Snehal filed to buy 5,602,302 shares at $27.5. January 14 '26 |
| Patel Snehal filed to buy 5,599,402 shares at $21.4. January 5 '26 |
| Patel Snehal filed to buy 5,595,102 shares at $21.7. January 2 '26 |
| Patel Snehal filed to buy 5,592,202 shares at $12.6. December 19 '25 |
Similar companies
Read more about Greenwich Lifesciences (GLSI) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions & customer reviews.
FAQ - Greenwich Lifesciences
The Market Cap of Greenwich Lifesciences is $373M.
Currently, the price of one share of Greenwich Lifesciences stock is $26.54.
The GLSI stock price chart above provides a comprehensive visual representation of Greenwich Lifesciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Greenwich Lifesciences shares. Our platform offers an up-to-date GLSI stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Greenwich Lifesciences (GLSI) does not offer dividends to its shareholders. Investors interested in Greenwich Lifesciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Greenwich Lifesciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
